Abstract
Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Current Molecular Medicine
Title:Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Volume: 13 Issue: 6
Author(s): N. Munoz-Durango, M.F. Barake, N.A. Letelier, C. Campino, C.E. Fardella and A.M. Kalergis
Affiliation:
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Abstract: Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Export Options
About this article
Cite this article as:
Munoz-Durango N., Barake M.F., Letelier N.A., Campino C., Fardella C.E. and Kalergis A.M., Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage, Current Molecular Medicine 2013; 13 (6) . https://dx.doi.org/10.2174/1566524011313060015
DOI https://dx.doi.org/10.2174/1566524011313060015 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: All Roads of Renal Hypertension Lead to or Come from CKD)
Current Hypertension Reviews Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Cocoa Polyphenols: Evidence from Epidemiological Studies
Current Pharmaceutical Design Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Does the Acupoint Specificity Exist? Evidence from Functional Neuroimaging Studies
Current Medical Imaging A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Current Traditional Medicine Human Inter-Individual DNA Sequence Variation in Candidate Genes, Drug Targets, the Importance of Haplotypes and Pharmacogenomics
Current Pharmaceutical Biotechnology Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Mitochondria-Associated Membranes (MAMs): A Novel Therapeutic Target for Treating Metabolic Syndrome
Current Medicinal Chemistry Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews Isolated Systolic Hypertension: Epidemiology, Pathogenesis and Treatment
Current Hypertension Reviews Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Cubosomes as Carriers for MRI Contrast Agents
Current Medicinal Chemistry Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Adiponectin - A Novel Anti-Atherogenic Factor in the Metabolic Syndrome: Mechanisms of Action and Therapeutic Potential
Vascular Disease Prevention (Discontinued) Influence of Vanin-1 and Catalytic Products in Liver During Normal and Oxidative Stress Conditions
Current Medicinal Chemistry Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Drug Safety MEET THE GUEST EDITOR
Combinatorial Chemistry & High Throughput Screening